Drug Profile
Research programme: superoxide dismutase 1 targeting therapeutics - Thera Neuropharma
Alternative Names: RNA interference-based therapeutics - Thera Neuropharma; sd-rxRNA® based therapeutics - Thera Neuropharma; SOD1 targeting sd-rxRNA therapeutics - Thera Neuropharma; THN 1Latest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator Thera Neuropharma
- Developer Phio Pharmaceuticals; Thera Neuropharma
- Class Small interfering RNA; Small molecules
- Mechanism of Action RNA interference; Superoxide dismutase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 20 Sep 2023 Preclinical development is ongoing in Amyotrophic-lateral-sclerosis in USA (Parenteral)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)
- 19 Nov 2018 RXi Pharmaceuticals is now called Phio Pharmaceuticals